Data as of May 24
| -0.11 / -2.21%|
The 1 analysts offering 12-month price forecasts for SciClone Pharmaceuticals Inc have a median target of 8.25, with a high estimate of 8.25 and a low estimate of 8.25. The median estimate represents a +69.75% increase from the last price of 4.86.
The current consensus among 2 polled investment analysts is to Outperform stock in SciClone Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.